IT is frequently difficult to predict the likely course of patients with malignant diseases. With increasing awareness of the role of " host " resistance in this context, many workers have been stimulated into searching for immunological methods for assessing the strength of this resistance and its role in prognosis.
As recent evidence suggests that the major part of the immunological response to neoplasia is cellular (Hellstrom and Hellstrom, 1969; Burnet, 1970) , it is obviously important to evaluate cell mediated reactions in patients with cancer. The cutaneous delayed hypersensitivity response to naturally occurring antigens has been used as an in vivo assessment of cellular immnunity in subjects with malignant diseases (Solowey and Rapaport, 1965; Hughes and Mackay, 1965) . These workers have demonstrated decreased responsiveness to the antigens employed in patients with advanced neoplasia. Since " positive " results rely upon prior exposure to the antigen, a " negative " result to one or more antigens may be of little relevance in determining anergy. This defect can be overcome by sensitizing patients to artificial allergenic chemicals to which they have not previously been exposed. One such chemical allergen is 2-4 dinitrochlorobenzene (DNCB) which will induce 95%o sensitization in normal individuals (Eilber and Morton, 1970) . In recent studies using this chemical, these authors have shown that patients who are anergenic to DNCB have a high incidence of early recurrence of malignant disease following surgical resections.
The present study was undertaken to investigate the relationship between the initial delayed hypersensitivity reaction to DNCB, following sensitization, in patients with gastrointestinal tumours and their subsequent survival.
MATERIALS AND METHODS
Seventy patients with gastrointestinal tumours were studied during this investigation. Table I itemizes the tumours studied. There were 38 males and 32 females and their ages ranged from 36 to 81 years (mean 63 years). No patients receiving x irradiation, chemotherapeutic agents or steroids were included. Patients who were found to be uraemic, who died during the operation or in the immediate post-operative period were also excluded.
Twenty " control " patients were obtained from the same hospital population. All were admitted for large bowel investigation and their consent was obtained before being included in this study. Their investigations 
RESULTS
The results of the delayed hypersensitivity reactions to DNCB in the cancer patients and controls are recorded in Table II . Grades i and ii have been grouped together because of the small numbers in these groups. The cancer patients were divided almost equally between the 4 groups with no significant difference between the proportions in each group (X2 6-21, d .f. -3, P 0 1). All but one of the control patients showed a delayed hypersensitivity reaction to DNCB and the majority were graded iii. If the cancer and control patients were graded as either " positive " or " negative " (Table III) there was a highly significant difference between them P -0-02 (Fisher's exact test). When the cancer patients' survival was compared with their initial DNCB sensitivity grading (Fig.) there was a striking correlation between their relative anergy and their subsequent progress. All but 2 patients in the Negative and Grade i categories were already dead at the time of the review, the longest recorded survival being only 9 months, whereas in Grades ii, iii and iv there had been only 2 deaths and patients had survived for up to 12 months (which was the maximum period possible at the time of this review).
In Table IV the initial DNCB responses have been compared with the 6-month mortality figures, excluding all patients who were alive but who had not yet reached 6 months of follow up. There was a significant difference between these 
